AstraZeneca's Imfinzi (durvalumab) plus chemotherapy, has gained CHMP recommendation for approval in the EU to treat NSCLC.

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in EFS with the durvalumab regimen vs the placebo regimen. Topline results were ...

member of the AEGEAN Steering Committee and investigator in the trial, said: "Adding perioperative durvalumab to neoadjuvant chemotherapy significantly improved outcomes for patients with ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

The Cambridge, England-based pharmaceuticals firm said Imfinzi, or durvalumab, in combination ... and was based on results from the Aegean phase three trial. In the trial, the drug showed a ...